Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment

Kazuyuki Matsushita, Toshiko Kajiwara, Sakae Itoga, Mamoru Satoh, Kazuyuki Sogawa, Hiroshi Umemura, Setsu Sawai, Motoi Nishimura, Mai Tamura, Nobuko Tanaka, Hideaki Shimada, Takeshi Tomonaga, Fumio Nomura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Development of useful biomarkers is pivotal for prediction of micro-metastasis, recurrence probability and/or prognosis of the patients. Recent studies have revealed that cancer-specific alternative splicing can be valuable for cancer cell detection. Among them, FUSE-binding protein-interacting repressor, FIR, has been reported to repress c-myc transcription and its exon2-spliced variant, FIRDelta(exon)2, is unable to repress c-myc by competing with authentic FIR in vivo and in vitro. Moreover FIRDelta(exon)2 was frequently discovered in human primary colorectal cancers, but not in the adjacent normal tissues, indicating its cancer-related expression. Thus, the expression level of FIRDelta(exon)2 mRNA in the colorectal cancer tissues as tumor marker candidates is examined. Further, to determine the interacting proteins, FIR-flag or FIRDelta(exon)2-flag stably expressing HeLa cells have been established by G418 selection and nuclear proteins were co immunoprecipitated with flag-conjugated magnetic beads. Those co-immunoprecipitated proteins with FIR or FIRDelta(exon)2 are candidates of tumor makers. In addition, substances that interfers FIR mRNA splicing should be anti-cancer drugs. Together, FIR splicing variant, FIRDelta(exon)2 mRNA or proteins and its interacting proteins are applicable for novel screening tumor markers in colorectal cancer detection.

Original languageEnglish
Pages (from-to)1151-1158
Number of pages8
JournalRinsho byori. The Japanese journal of clinical pathology
Volume57
Issue number12
Publication statusPublished - Dec 2009
Externally publishedYes

Fingerprint

Alternative Splicing
Exons
Colorectal Neoplasms
Neoplasms
Tumor Biomarkers
Messenger RNA
Proteins
Therapeutics
Nuclear Proteins
HeLa Cells
poly-U binding splicing factor 60KDa
Biomarkers
Neoplasm Metastasis
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment. / Matsushita, Kazuyuki; Kajiwara, Toshiko; Itoga, Sakae; Satoh, Mamoru; Sogawa, Kazuyuki; Umemura, Hiroshi; Sawai, Setsu; Nishimura, Motoi; Tamura, Mai; Tanaka, Nobuko; Shimada, Hideaki; Tomonaga, Takeshi; Nomura, Fumio.

In: Rinsho byori. The Japanese journal of clinical pathology, Vol. 57, No. 12, 12.2009, p. 1151-1158.

Research output: Contribution to journalArticle

Matsushita, K, Kajiwara, T, Itoga, S, Satoh, M, Sogawa, K, Umemura, H, Sawai, S, Nishimura, M, Tamura, M, Tanaka, N, Shimada, H, Tomonaga, T & Nomura, F 2009, 'Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment', Rinsho byori. The Japanese journal of clinical pathology, vol. 57, no. 12, pp. 1151-1158.
Matsushita, Kazuyuki ; Kajiwara, Toshiko ; Itoga, Sakae ; Satoh, Mamoru ; Sogawa, Kazuyuki ; Umemura, Hiroshi ; Sawai, Setsu ; Nishimura, Motoi ; Tamura, Mai ; Tanaka, Nobuko ; Shimada, Hideaki ; Tomonaga, Takeshi ; Nomura, Fumio. / Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment. In: Rinsho byori. The Japanese journal of clinical pathology. 2009 ; Vol. 57, No. 12. pp. 1151-1158.
@article{c0fc6ab8cab64062b44474b2eb152c41,
title = "Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment",
abstract = "Development of useful biomarkers is pivotal for prediction of micro-metastasis, recurrence probability and/or prognosis of the patients. Recent studies have revealed that cancer-specific alternative splicing can be valuable for cancer cell detection. Among them, FUSE-binding protein-interacting repressor, FIR, has been reported to repress c-myc transcription and its exon2-spliced variant, FIRDelta(exon)2, is unable to repress c-myc by competing with authentic FIR in vivo and in vitro. Moreover FIRDelta(exon)2 was frequently discovered in human primary colorectal cancers, but not in the adjacent normal tissues, indicating its cancer-related expression. Thus, the expression level of FIRDelta(exon)2 mRNA in the colorectal cancer tissues as tumor marker candidates is examined. Further, to determine the interacting proteins, FIR-flag or FIRDelta(exon)2-flag stably expressing HeLa cells have been established by G418 selection and nuclear proteins were co immunoprecipitated with flag-conjugated magnetic beads. Those co-immunoprecipitated proteins with FIR or FIRDelta(exon)2 are candidates of tumor makers. In addition, substances that interfers FIR mRNA splicing should be anti-cancer drugs. Together, FIR splicing variant, FIRDelta(exon)2 mRNA or proteins and its interacting proteins are applicable for novel screening tumor markers in colorectal cancer detection.",
author = "Kazuyuki Matsushita and Toshiko Kajiwara and Sakae Itoga and Mamoru Satoh and Kazuyuki Sogawa and Hiroshi Umemura and Setsu Sawai and Motoi Nishimura and Mai Tamura and Nobuko Tanaka and Hideaki Shimada and Takeshi Tomonaga and Fumio Nomura",
year = "2009",
month = "12",
language = "English",
volume = "57",
pages = "1151--1158",
journal = "Rinsho byori. The Japanese journal of clinical pathology",
issn = "0047-1860",
publisher = "Nihon Rinsho Byori Gakkai",
number = "12",

}

TY - JOUR

T1 - Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment

AU - Matsushita, Kazuyuki

AU - Kajiwara, Toshiko

AU - Itoga, Sakae

AU - Satoh, Mamoru

AU - Sogawa, Kazuyuki

AU - Umemura, Hiroshi

AU - Sawai, Setsu

AU - Nishimura, Motoi

AU - Tamura, Mai

AU - Tanaka, Nobuko

AU - Shimada, Hideaki

AU - Tomonaga, Takeshi

AU - Nomura, Fumio

PY - 2009/12

Y1 - 2009/12

N2 - Development of useful biomarkers is pivotal for prediction of micro-metastasis, recurrence probability and/or prognosis of the patients. Recent studies have revealed that cancer-specific alternative splicing can be valuable for cancer cell detection. Among them, FUSE-binding protein-interacting repressor, FIR, has been reported to repress c-myc transcription and its exon2-spliced variant, FIRDelta(exon)2, is unable to repress c-myc by competing with authentic FIR in vivo and in vitro. Moreover FIRDelta(exon)2 was frequently discovered in human primary colorectal cancers, but not in the adjacent normal tissues, indicating its cancer-related expression. Thus, the expression level of FIRDelta(exon)2 mRNA in the colorectal cancer tissues as tumor marker candidates is examined. Further, to determine the interacting proteins, FIR-flag or FIRDelta(exon)2-flag stably expressing HeLa cells have been established by G418 selection and nuclear proteins were co immunoprecipitated with flag-conjugated magnetic beads. Those co-immunoprecipitated proteins with FIR or FIRDelta(exon)2 are candidates of tumor makers. In addition, substances that interfers FIR mRNA splicing should be anti-cancer drugs. Together, FIR splicing variant, FIRDelta(exon)2 mRNA or proteins and its interacting proteins are applicable for novel screening tumor markers in colorectal cancer detection.

AB - Development of useful biomarkers is pivotal for prediction of micro-metastasis, recurrence probability and/or prognosis of the patients. Recent studies have revealed that cancer-specific alternative splicing can be valuable for cancer cell detection. Among them, FUSE-binding protein-interacting repressor, FIR, has been reported to repress c-myc transcription and its exon2-spliced variant, FIRDelta(exon)2, is unable to repress c-myc by competing with authentic FIR in vivo and in vitro. Moreover FIRDelta(exon)2 was frequently discovered in human primary colorectal cancers, but not in the adjacent normal tissues, indicating its cancer-related expression. Thus, the expression level of FIRDelta(exon)2 mRNA in the colorectal cancer tissues as tumor marker candidates is examined. Further, to determine the interacting proteins, FIR-flag or FIRDelta(exon)2-flag stably expressing HeLa cells have been established by G418 selection and nuclear proteins were co immunoprecipitated with flag-conjugated magnetic beads. Those co-immunoprecipitated proteins with FIR or FIRDelta(exon)2 are candidates of tumor makers. In addition, substances that interfers FIR mRNA splicing should be anti-cancer drugs. Together, FIR splicing variant, FIRDelta(exon)2 mRNA or proteins and its interacting proteins are applicable for novel screening tumor markers in colorectal cancer detection.

UR - http://www.scopus.com/inward/record.url?scp=77949332640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949332640&partnerID=8YFLogxK

M3 - Article

C2 - 20077813

AN - SCOPUS:77949332640

VL - 57

SP - 1151

EP - 1158

JO - Rinsho byori. The Japanese journal of clinical pathology

JF - Rinsho byori. The Japanese journal of clinical pathology

SN - 0047-1860

IS - 12

ER -